PF-Atlas › Clinical Trials › NCT01844778

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder Versus Nebulised Tobramycin Inhalation Solution and Nebulised Colistimethate

Tobramycin Inhalation Powder · Phase 4

Registry ID
NCT01844778
Phase
Phase 4
Status
Completed
Drug / intervention
Tobramycin Inhalation Powder
Sponsor
Novartis Pharmaceuticals
Start
2013-08
Enrollment
60
Locations
21

About this trial

The purpose of this interventional Phase IV study was to explore the ease of use of TIP and prevalence of microbial contamination of the T-326 Inhaler compared with TIS and colistimethate administered via nebuliser for the treatment of Cystic Fibrosis (CF) patients chronically infected with P. aeruginosa. It was anticipated that the data from this study would provide clinicians with further guidance on the relative differences between the speed and ease of use of these treatments as well as useful information on the prevalence of microbial contamination of the inhalation devices in "real world" use.

View NCT01844778 on ClinicalTrials.gov →

Explore related

All Tobramycin Inhalation Powder trialsAll IPF trials

Related trials

Tobramycin inhalation powder — NCT00982930Tobramycin Inhalation Powder — NCT00125346
Medical disclaimer. This page summarizes public trial data for NCT01844778 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.